SHANGHAI — Encorafenib (Braftovi®), a potent, highly selective BRAF kinase inhibitor approved in China in June 2025, is now officially available at Jiahui International Cancer Center. Indicated in combination with cetuximab for adult patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) after prior systemic therapy, this regimen brings a new precision-medicine option to one of the most challenging colorectal cancer subtypes.

"Encorafenib marks the beginning of a new era of targeted combination therapy for BRAF-mutated colorectal cancer in China, bringing new survival hope to patients who have failed later-line treatment."

A Precision Breakthrough for BRAF V600E+ Metastatic Colorectal Cancer

Colorectal cancer is one of the most common malignancies in China. Approximately 7% of patients carry the BRAF V600E mutation. These patients typically respond poorly to conventional chemotherapy, experience rapid disease progression, and have limited treatment options, posing a significant survival challenge.

The encorafenib plus cetuximab combination precisely targets BRAF V600E-mutated mCRC, particularly as a later-line option after prior treatment failure. By potently inhibiting mutant BRAF protein activity and blocking the MAPK signaling pathway, encorafenib effectively suppresses tumor growth and spread, providing a clear targeted treatment pathway for this high-risk subgroup.

Improved Response Rates and Durable Remission

Encorafenib demonstrated outstanding efficacy in the pivotal Phase III BREAKWATER study:

• Objective Response Rate (ORR): 60.9%, significantly higher than the 40.0% seen with traditional chemotherapy plus bevacizumab.
• Median Duration of Response (mDoR): 13.9 months, longer than the 11.1 months in the control group, suggesting more durable treatment response.
• Favorable Safety Profile: The most common adverse reactions were fatigue and arthralgia, mostly mild to moderate, with good patient tolerability.

Precision Testing and Whole-Journey Management

At Jiahui International Cancer Center, every patient undergoes a comprehensive diagnostic and treatment pathway designed to match the right therapy to the right tumor biology:

Genetic Testing First

Before treatment, BRAF V600E mutation status must be confirmed through a compliant, validated molecular test to ensure therapeutic precision.

One-Stop Personalized Treatment

Patients receive multidisciplinary team (MDT) evaluation at the Jiahui Cancer Center. A treatment plan centered on encorafenib is tailored to each individual's disease profile and overall health status.

Comprehensive Medication Monitoring

Clinical pharmacists and the nursing team closely monitor treatment response and safety, adjusting the regimen as needed to ensure smooth implementation and optimal outcomes.

Jiahui Pharmacy Services: Medication Support You Can Trust

Our Pharmacy Department provides comprehensive support throughout the treatment journey:

Drug Supply and Quality Management

• Drug sourcing and quality assurance: Strict adherence to GSP standards ensures reliable drug sourcing, compliant storage, and traceable dispensing.
• International originator drugs: Including lurbinectedin and other oncology agents, introduced to meet the special medication needs of cancer patients.

Clinical Rational Medication Support

• Pharmacists participate in multidisciplinary tumor boards, providing medication recommendations for complex cases.
• Therapeutic drug monitoring and individualized dose adjustment are implemented when clinically appropriate.
• Comprehensive pre-dispensing prescription review and manual verification ensure safe and standardized medication use.

Whole-Journey Patient Medication Education

We provide medication counseling, face-to-face medication guidance, bedside discharge medication education, and focused follow-up for patients receiving anticancer therapy for the first time. This improves treatment adherence, builds confidence, and supports better outcomes.

About Jiahui International Cancer Center

Jiahui International Cancer Center is part of Shanghai Jiahui International Hospital and serves as the strategic partner in China of Massachusetts General Hospital (MGH) and its cancer center, a Harvard Medical School-affiliated teaching hospital. Led by internationally experienced oncology specialists, the center provides rapid, globally standardized comprehensive cancer care for patients aged 14 and above.

What patients value at Jiahui:

• Internationally benchmarked facilities and clinical capabilities
• Multidisciplinary tumor boards and personalized treatment planning
• Access to globally approved oncology agents, including novel therapies
• Multilingual communication support for international patients
• Private, comfortable treatment environment
• Continuous clinical pharmacy and nursing monitoring